Incremental Propensity Score Interventions: A Primer for Pharmacoepidemiologists
Pharmacoepidemiology and Drug Safety · 2026
DOI: 10.1002/pds.70484 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmacoepidemiology and Drug Safety, 2026. Verfasst von Byeong Yeob Choi. Beteiligte Einrichtung: Department of Population Health Sciences, Long School of Medicine, UT San Antonio Health Science Center, San Antonio, Texas, USA. Hauptthemen laut MEDLINE: Propensity Score, Pharmacoepidemiology, Percutaneous Coronary Intervention, Immunoglobulin Fab Fragments. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, National Cancer Institute.
Abstract (Originalsprache)
Background
In observational pharmacoepidemiology, estimating average treatment effects (ATEs) is often challenging due to a lack of practical positivity. In highly selective clinical settings, certain patients almost always or never receive treatment, causing ATE estimators to rely on unstable extrapolation. Incremental propensity score interventions (IPSIs) offer a stochastic alternative by shifting each patient's probability of treatment, providing a more clinically realistic framework that circumvents positivity violations.
Methods
We illustrate the IPSI approach, including key identification results and inferential procedures. Using observational data from a cohort of 996 patients undergoing percutaneous coronary intervention (PCI), we evaluated the effect of shifting each patient's probability of receiving abciximab by a predetermined amount on six‐month mortality. Propensity scores (PSs) and outcome predictions were estimated using a machine learning ensemble (Super Learner) with 10‐fold sample splitting.
Results
The ATE estimate suggested that abciximab administration reduced the 6‐month mortality risk by 5.9 percentage points compared with PCI alone (risk difference = −0.059, 95% CI: −0.104 to −0.015). However, the practical interpretability of the ATE estimate may be limited because it implicitly assumes that patients with a near‐certain probability of treatment could realistically be assigned to withhold abciximab. In contrast, shifting each patient's treatment propensity by odds ratios ranging from 0.1 to 10 showed that 6‐month mortality would be significantly reduced under a strong treatment policy promoting abciximab administration.
Conclusions
IPSIs provide a robust and practical alternative to conventional causal inference methods in pharmacoepidemiology settings where treatment assignment is highly selective and the strict positivity is violated.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Population Health Sciences, Long School of Medicine, UT San Antonio Health Science Center, San Antonio, Texas, USA.
ORCID-Profile: Byeong Yeob Choi
Förderung
- NCI NIH HHS
- National Cancer Institute
Zitieren
APA
Choi, B. Y. (2026). Incremental Propensity Score Interventions: A Primer for Pharmacoepidemiologists. Pharmacoepidemiology and Drug Safety. https://doi.org/10.1002/pds.70484
Vancouver
Choi BY. Incremental Propensity Score Interventions: A Primer for Pharmacoepidemiologists. Pharmacoepidemiology and Drug Safety. 2026. doi:10.1002/pds.70484
BibTeX
@article{Choi2026,
author = {Choi, Byeong Yeob},
title = {Incremental Propensity Score Interventions: A Primer for Pharmacoepidemiologists},
journal = {Pharmacoepidemiology and Drug Safety},
year = {2026},
doi = {10.1002/pds.70484}
}
EUVIMED